Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Azithromycin Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Mortality Reduction After Oral Azithromycin: Morbidity Study

NCT02048007
View directory record Official record
Conditions
Childhood Mortality
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Month and older
Enrollment
72,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 4 Interventional

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease

NCT01014078
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Azithromycin Ophthalmic Solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jul 23, 2026, 4:04 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Infant Mortality Reduction by the Mass Administration of Azithromycin

NCT04716712
View directory record Official record
Conditions
Child Mortality
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Month to 11 Months
Enrollment
694,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 4 Interventional

Azithromycin in the Treatment of M. Avium Complex Lung Disease

NCT00599079
View directory record Official record
Conditions
Mycobacterium Avium Complex Lung Disease
Interventions
Azithromycin
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2017
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

NCT04010539
View directory record Official record
Conditions
Gonorrhea
Interventions
Gepotidacin, Ceftriaxone, Azithromycin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Palm Springs, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

NCT01102244
View directory record Official record
Conditions
Blepharitis
Interventions
Tobradex ST, Azasite
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jul 23, 2026, 4:04 AM EDT
Not yet recruiting Phase 4 Interventional

Extended Azithromycin Treatment in Prelabor Rupture of Membranes

NCT07669207
View directory record Official record
Conditions
Preterm Prelabor Rupture of Membranes, PPROM
Interventions
Azithromycin (Azithro), Standard Azithromycin Dosing
Drug
Lead sponsor
Alexa Henderson
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania

NCT00347607
View directory record Official record
Conditions
Trachoma
Interventions
community surveillance and re-treatment
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Months to 7 Years
Enrollment
2,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

YCFM (Youth Correctional Facilities Males)

NCT03249935
View directory record Official record
Conditions
Chlamydial Infection
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 21 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis

NCT01486758
View directory record Official record
Conditions
RSV Bronchiolitis
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Month to 18 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 2 Interventional

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

NCT00002192
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Rifapentine, Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Anderson Clinical Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 4:04 AM EDT
Terminated Phase 3 Interventional

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions
Clofazimine Inhalation Suspension, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Azithromycin for Meningococcal Carriage

NCT06618534
View directory record Official record
Conditions
Meningococcal Infections
Interventions
Azithromycin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 25 Years
Enrollment
764 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults

NCT00644293
View directory record Official record
Conditions
Pharyngitis, Tonsillitis
Interventions
azithromycin (Zithromax), placebo, azithromycin SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Clearwater, Florida • Boise, Idaho • Meridian, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 3 Interventional

A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections

NCT00643292
View directory record Official record
Conditions
Acute Otitis Media
Interventions
amoxicillin/clavulanate postassium (Augmentin ES-600), azithromycin SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 48 Months
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Bellflower, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

NCT00629941
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Lewiston, Maine • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 4 Interventional

A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media

NCT00645112
View directory record Official record
Conditions
Acute Otitis Media
Interventions
cefdinir (Omnicef), azithromycin
Drug
Lead sponsor
Abbott
Industry
Eligibility
6 Months to 6 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
30
States / cities
Columbiana, Alabama • Montgomery, Alabama • Ozark, Alabama + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2008 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Zoliflodacin in Uncomplicated Gonorrhoea

NCT03959527
View directory record Official record
Conditions
Gonorrhea
Interventions
zoliflodacin, ceftriaxone, azithromycin
Drug
Lead sponsor
Global Antibiotics Research and Development Partnership
Other
Eligibility
12 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose, Three-Way, Three-Sequence, Crossover BA Study of Azithromycin Oleogel

NCT05796362
View directory record Official record
Conditions
Infectious Disease, Drug Effect, Clinical Infection
Interventions
Azithromycin Oleogel (Oral and Rectal)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis

NCT00629590
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Wantagh, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease

NCT04358081
View directory record Official record
Conditions
Covid-19
Interventions
HCQ, HCQ+AZT, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Fullerton, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 4 Interventional

Azithromycin Dose and PPROM Treatment: a Pilot Randomized Controlled Trial

NCT04294069
View directory record Official record
Conditions
Preterm Premature Rupture of Membrane
Interventions
Azithromycin 500 mg, Azithromycin Oral Product
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
14 Years to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 23, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS

NCT00000966
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Azithromycin, Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Worcester, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2008 · Synced Jul 23, 2026, 4:04 AM EDT
Terminated Phase 3 Interventional Results available

AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department

NCT04669288
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Months to 60 Months
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 4:04 AM EDT